{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:40:27Z","timestamp":1775817627710,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T00:00:00Z","timestamp":1272240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T00:00:00Z","timestamp":1272240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:p>\n                    <jats:bold>Background and purpose:\u2002<\/jats:bold>\n                    Statins (HMG CoA reductase inhibitors) have beneficial effects independent of reducing cholesterol synthesis and this includes their ability to acutely activate endothelial nitric oxide synthase (eNOS). The mechanism by which this occurs is largely unknown and thus we characterized the pathways by which statins activate NOS, including involvement of scavenger receptor\u2010B1 (SR\u2010B1), which is expressed in endothelial cells and maintains cholesterol concentrations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Experimental approach:\u2002<\/jats:bold>\n                    Nitric oxide production was monitored in bovine aortic endothelial cells (BAECs) exposed to lovastatin (LOV) or pravastatin (PRA) for 10\u201320\u2003min, alone or following pre\u2010exposure to the end product of HMG\u2010CoA reductase (mevalonate), G protein inhibitors (pertussis\/cholera toxins), phospholipase C (PLC) inhibitor (U\u201073122), or intracellular and extracellular calcium chelators \u2013 BAPTA\u2010AM and EGTA (respectively), or a function blocking antibody to SR\u2010B1.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Key results:\u2002<\/jats:bold>\n                    Both statins increased NO production in a rapid, dose\u2010dependent and HMG\u2010CoA reductase\u2010independent manner. Inhibiting Gi protein or PLC almost completely blocked statin\u2010induced NO generation. Additionally, removing extracellular calcium inhibited statin\u2010induced NO production. COS\u20107 cells co\u2010transfected with eNOS and SR\u2010B1 increased NO production when exposed to LOV or high\u2010density lipoprotein (HDL), an agonist of SR\u2010B1. These effects were not observed in COS\u20107 cells with eNOS alone or co\u2010transfected with bradykinin receptor 2, indicating specificity for SR\u2010B1. Further, pretreatment of BAEC with blocking antibody for SR\u2010B1 blocked NO responses to statins and HDL.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions and implications:\u2002<\/jats:bold>\n                    LOV and PRA acutely activate eNOS through pathways that include the cell surface receptor SR\u2010B1, Gi protein, phosholipase C and entry of extracellular calcium into endothelial cells.\n                  <\/jats:p>","DOI":"10.1111\/j.1476-5381.2010.00817.x","type":"journal-article","created":{"date-parts":[[2010,4,26]],"date-time":"2010-04-26T10:32:25Z","timestamp":1272277945000},"page":"1765-1772","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Acute activation of eNOS by statins involves scavenger receptor\u2010B1, G protein subunit Gi, phospholipase C and calcium influx"],"prefix":"10.1111","volume":"160","author":[{"given":"R","family":"Datar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WH","family":"Kaesemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DJ","family":"Fulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RW","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23858"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240404"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505968200"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(01)00306-6"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.05.028"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.25.3227"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-000-0091-3"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-000-0022-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-002-0032-4"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/21218"},{"key":"e_1_2_9_12_1","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Group SSSS","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00214.2004"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.060574"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00680-9"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00514-2"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.2001.281.6.C1743"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.199059"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.58.12.0010"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(00)00146-2"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI14011"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/79510"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2605.2006.00695.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.12.1129"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.2.178"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.45.120403.095748"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.06.023"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E03-06-0445"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb03818.x"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000066286.15621.98"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704487"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.630194"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.15.11278"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.11.6435"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00167177"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000099503.13312.7B"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.01.066"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(01)00191-7"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-200004000-00008"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/89986"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2010.00817.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2010.00817.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/j.1476-5381.2010.00817.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2010.00817.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:07:58Z","timestamp":1773004078000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2010.00817.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,26]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1476-5381.2010.00817.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00817.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,26]]},"assertion":[{"value":"2010-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}